Cliff Asness's ACAD Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 620,832 shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $13.25 M, representing 0.01% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ACAD, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 329,129 shares. Largest reduction occurred in Q3 2020, reducing 78,728 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +102,475 | Add 0.00% | 102,474 | $4.65 |
| Q2 2013 | +79,675 | Add 0.00% | 79,674 | $18.15 |
| Q3 2013 | +8,700 | Add 10.92% | 88,374 | $27.47 |
| Q4 2013 | -11,300 | Reduce 12.79% | 77,074 | $24.99 |
| Q1 2014 | -50,500 | Reduce 65.52% | 26,574 | $24.35 |
| Q2 2014 | +72,800 | Add 273.95% | 99,374 | $22.59 |
| Q3 2014 | -62,000 | Reduce 62.39% | 37,374 | $24.75 |
| Q4 2014 | -3,600 | Reduce 9.63% | 33,774 | $31.74 |
| Q1 2015 | -6,000 | Reduce 17.77% | 27,774 | $32.58 |
| Q2 2015 | +10,845 | Add 39.05% | 38,619 | $41.90 |
| Q3 2015 | -23,486 | Reduce 60.81% | 15,133 | $33.04 |
| Q4 2015 | +22,618 | Add 149.46% | 37,751 | $35.65 |
| Q1 2016 | -5,566 | Reduce 14.74% | 32,185 | $27.96 |
| Q2 2016 | -16,751 | Reduce 52.05% | 15,434 | $32.46 |
| Q3 2016 | -15,434 | Sold Out | 15,434 | $0.00 |
| Q1 2017 | +35,246 | New Buy | 35,246 | $34.39 |
| Q2 2017 | +3,414 | Add 9.69% | 38,660 | $27.88 |
| Q4 2017 | -2,097 | Reduce 5.42% | 36,563 | $30.11 |
| Q1 2018 | -7,038 | Reduce 19.25% | 29,525 | $22.46 |
| Q2 2018 | -29,525 | Sold Out | 29,525 | $0.00 |
| Q4 2018 | +74,727 | New Buy | 74,727 | $16.17 |
| Q1 2019 | +29,050 | Add 38.87% | 103,777 | $26.85 |
| Q2 2019 | +27,905 | Add 26.89% | 131,682 | $26.73 |
| Q3 2019 | +20,699 | Add 15.72% | 152,381 | $35.99 |
| Q4 2019 | -17,984 | Reduce 11.80% | 134,397 | $42.78 |
| Q1 2020 | -22,533 | Reduce 16.77% | 111,864 | $42.25 |
| Q2 2020 | -11,906 | Reduce 10.64% | 99,958 | $48.47 |
| Q3 2020 | -78,728 | Reduce 78.76% | 21,230 | $41.26 |
| Q4 2020 | -9,759 | Reduce 45.97% | 11,471 | $53.44 |
| Q1 2021 | -2,810 | Reduce 24.50% | 8,661 | $25.75 |
| Q2 2021 | -8,661 | Sold Out | 8,661 | $0.00 |
| Q4 2021 | +27,693 | New Buy | 27,693 | $23.33 |
| Q1 2022 | +11,275 | Add 40.71% | 38,968 | $24.23 |
| Q2 2022 | +8,296 | Add 21.29% | 47,264 | $14.09 |
| Q3 2022 | -7,361 | Reduce 15.57% | 39,903 | $16.36 |
| Q4 2022 | +5,531 | Add 13.86% | 45,434 | $15.92 |
| Q1 2023 | -5,048 | Reduce 11.11% | 40,386 | $18.82 |
| Q2 2023 | +5,805 | Add 14.37% | 46,191 | $23.95 |
| Q3 2023 | +1,936 | Add 4.19% | 48,127 | $20.84 |
| Q4 2023 | +1,120 | Add 2.33% | 49,247 | $31.31 |
| Q1 2024 | -1,700 | Reduce 3.45% | 47,547 | $18.49 |
| Q2 2024 | -11,356 | Reduce 23.88% | 36,191 | $16.25 |
| Q3 2024 | +737 | Add 2.04% | 36,928 | $15.38 |
| Q4 2024 | +28,252 | Add 76.51% | 65,180 | $18.35 |
| Q1 2025 | +2,492 | Add 3.82% | 67,672 | $16.61 |
| Q2 2025 | +224,031 | Add 331.05% | 291,703 | $21.57 |
| Q3 2025 | +329,129 | Add 112.83% | 620,832 | $21.34 |
Cliff Asness's ACADIA Pharmaceuticals Investment FAQs
Cliff Asness first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q4 2012, acquiring 102,474 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held ACADIA Pharmaceuticals Inc. (ACAD) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q3 2025, adding 620,832 shares worth $13.25 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 620,832 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $13.25 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 620,832 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.